Targeting mitochondria in lung cancer treatment
Targeting tumor cell mitochondria for the prevention and treatment of lung cancer
['FUNDING_R01'] · UNIVERSITY OF MINNESOTA · NIH-11047011
This study is testing a new drug called mitomet that aims to help people with lung cancer, especially those with tough-to-treat tumors, by making cancer cells more vulnerable to stress, which could lead to better treatment results.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MINNESOTA (nih funded) |
| Locations | 1 site (MINNEAPOLIS, UNITED STATES) |
| Trial ID | NIH-11047011 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new treatments for lung cancer, specifically targeting tumors with mutations in the Kras and LKB1 genes. The approach involves using a specialized drug, mitomet, which is designed to accumulate in the mitochondria of cancer cells and increase oxidative stress, potentially leading to cancer cell death. By enhancing the vulnerability of these tumors to oxidative stress, the research aims to improve treatment outcomes, especially for aggressive lung cancers that are resistant to current therapies. Patients may have the opportunity to participate in trials assessing the effectiveness of this novel treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung adenocarcinoma, particularly those with Kras and LKB1 mutations.
Not a fit: Patients with lung cancer types that do not involve Kras or LKB1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with aggressive lung cancer.
How similar studies have performed: Previous research has shown promise in targeting mitochondrial pathways in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
MINNEAPOLIS, UNITED STATES
- UNIVERSITY OF MINNESOTA — MINNEAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KASSIE, FEKADU — UNIVERSITY OF MINNESOTA
- Study coordinator: KASSIE, FEKADU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.